Related Experiment Video
Updated: Jun 8, 2026

13:36
Utilizing the Antigen Capsid-Incorporation Strategy for the Development of Adenovirus Serotype 5-Vectored Vaccine Approaches
Published on: May 6, 2015
Lessons from the failure of the adenovector HIV vaccine
Marie-Eve Blais1, Sarah Rowland-Jones
1MRC Human Immunology Unit, Weatherall Institute of Molecular Medicine, John Radcliffe Hospital Oxford OX3 9DS UK.
F1000 Biology Reports
|October 16, 2010
Abstract:
The much-publicised halting of the joint Merck/HIV Vaccine Trials Network phase IIB candidate HIV-1 vaccine trial in 2007 has led to an unprecedented degree of discussion and introspection amongst the HIV research community. In this commentary, we will summarise the lessons learned from the trial and examine the current state of HIV vaccine research.

